BDMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BDMD is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has no strong bullish proprietary signal, no recent news catalyst, neutral insider and hedge fund activity, weak financials, and a bearish near-term price tendency from pattern analysis. Despite a slightly positive technical setup, the overall evidence does not support an immediate buy.
The technical picture is mixed to slightly positive. MACD histogram is positive and expanding, which supports short-term upside momentum. RSI_6 at 64.667 is neutral-to-bullish but not overbought. Moving averages are converging, suggesting the stock is still searching for direction rather than in a strong established uptrend. Current price 1.86 is below the first resistance at 1.944 and above pivot support at 1.795, so the stock is sitting in a narrow range. However, the pattern-based trend estimate points to weakness ahead, with a 70% chance of -3.1% next day, -7.25% next week, and -11.93% next month, which outweighs the mild technical improvement.
["MACD histogram is above zero and expanding, showing improving momentum.", "Current price is holding above the pivot level at 1.795.", "Gross margin in Q2 2024 was high at 83.79%, indicating strong product economics."]
["No news in the recent week, so there are no event-driven upside catalysts.", "Hedge funds are neutral and insiders are neutral, with no meaningful accumulation signal.", "Pattern analysis suggests a bearish near-term path with downside probabilities over the next day, week, and month.", "Revenue was 0 in 2024/Q2, and net income remained negative at -858,731, with EPS at -0.98.", "No valuation data is available, making it harder to justify a long-term entry.", "AI Stock Picker shows no signal today and SwingMax shows no recent signal."]
In Q2 2024, BDMD reported revenue of 0, which is flat year over year and indicates no top-line growth. Net income was -858,731, also flat YoY but still negative, and EPS was -0.98, remaining unprofitable. Gross margin was 83.79, which is strong, but the lack of revenue growth and continued losses make the latest quarter weak for a long-term buy case.
No analyst rating or price target change data was provided, so there is no visible recent Wall Street upgrade/downgrade trend or target revision trend to support a bullish view. Based on the available data, Wall Street pros would likely lean cautious: the positives are strong gross margin and some technical momentum, while the negatives are no revenue growth, continued losses, no fresh news catalyst, and no proprietary buy signal.
